Modality
Cell Therapy
MOA
JAK1/2i
Target
KRASG12C
Pathway
Epigenetic
GBMMelanomaGA
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Apr 2027
Phase 1Current
NCT05282626
1,595 pts·GBM
2017-08→2027-04·Completed
1,595 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-211.1y awayInterim· GBM
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Complet…
Catalysts
Interim
2027-04-21 · 1.1y away
GBM
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05282626 | Phase 1 | GBM | Completed | 1595 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Pemitapinarof | BeiGene | Approved | KRASG12C |